Blood Res.  2023 Apr;58(S1):11-12. 10.5045/br.2023.2023015.

Practical issues in CAR T-cell therapy

• Byun JM

• KMID: 2541977
• DOI: http://doi.org/10.5045/br.2023.2023015

Abstract

Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.

Keyword

CAR T-cell therapy; Korea; Patient access; Barrier